Surgical Oncology
Volume 19, Issue 2 , Pages 63-81 , June 2010

Drugs of anaesthesia and cancer

,Accepted 16 March 2009.

References 

  1. Kvolik S, Glavas-Obrovac L, Bares V, Karner I. Effects of inhalation anaesthetics halothane, sevoflurane, and isoflurane on human cell lines. Life Sci. 2005;77:2369–2383
  2. Mammoto T, Mukai M, Mammoto A, Yamanaka Y, Hayashi Y, Mashimo T, et al. Intravenous anaesthetic, propofol inhibits invasion of cancer cells. Cancer Lett. 2002;184:165–170
  3. Tatsuya I, Tsunehisa N, Kazuhiko F, Gregg LS, Kiichi H. Reversible inhibition of hypoxia-inducible factor 1 activation by exposure of hypoxic cells to the volatile anesthetic halothane. FEBS Lett. 2001;509:225–229
  4. Melamed R, Bar-Yosef S, Shakhar G, Shakhar K, Ben-Eliyahu S. Suppression of natuarl killer cell activity and promotion of tumour metastasis by ketamine, thiopental, and halothane, but not by propofol: mediating mechanisms and prophylactic measures. Anesth Analg. 2003;97:1331–1339
  5. Van de Louw A, Plaud B, Debaene B. Use of sevoflurane for surgery of phaeochromocytoma. Ann Fr Anesth Reanim. 1998;17:301–305
  6. ASA ad hoc Committee on Effects of Trace Anaesthetics on the Operating Room Personnel . Occupational disease among operating room personnel: a national study. Anesthesiology. 1974;41:321–340
  7. Mazze RI, Fujinaga M, Rice SA, Harris SB, Baden JM. Reproductive and teratogenic effects of nitrous oxide, halothane, isoflurane, and enflurane in Sprague–Dawley rats. Anesthesiology. 1986;64:339–344
  8. Eger EI, White AE, Brown CL, Biava CG, Corbett TH, Stevens WC. A test of the carcinogenicity of enflurane, isoflurane, halothane, methoxyflurane and nitrous oxide in mice. Anaesth Analg. 1978;57:678–694
  9. Brasil LJ, San-Miguel B, Kretzmann NA, Gomes Do Amaral JL, Zettler CG, Marroni N, et al. Halothane induces oxidative stress and NF-kB activation in rat liver: protective effect of propofol. Toxicology. 2007;227:53–61
  10. Katzav S, Shapiro J, Segal S, Feldman M. General anesthesia during excision of a mouse tumor accelerates postsurgical growth of metastases by suppression of natural killer cell activity. Isr J Med Sci. 1986;22:339–345
  11. Waxler B, Zhang X, Wezeman FH. Anesthetic agents modify tissue proteinase inhibitor content and tumor behaviour. J Lab Clin Med. 1994;123:53–58
  12. Page GG, Ben-Eliyahu S. Increased surgery-induced metastasis and suppressed natural killer cell activity during proestrus/estrus in rats. Breast Cancer Res Treat. 1997;45:159–167
  13. Bar-Yosef S, Melamed R, Page GG, Shakhar G, Shakhar K, Ben-Eliyahu S. Attenuation of the tumor-promoting effect of surgery by spinal blockade in rats. Anesthesiology. 2001;94:1066–1073
  14. Valtcheva R, Stephanova E, Jordanova A, Pankov R, Altankov G, Lalchev Z. Effect of halothane on lung carcinoma cells A 549. Chem Biol Interact. 2003;146:191–200
  15. Tas PW, Roewer N. The volatile anesthetic enflurane activates capacitative Ca2+ channels in rat glioma C6 cells. Toxicol Lett. 1998;100-101:265–269
  16. Singh G, Janicki PK, Horn JL, Janson VE, Franks JJ. Inhibition of plasma membrane Ca(2+)-ATPase pump activity in cultured C6 glioma cells by halothane and xenon. Life Sci. 1995;56:219–224
  17. Atcheson R, Bjornstrom K, Hirst RA, Rowbotham DJ, Lambert DG. Effect of halothane on K+ and carbachol stimulated [3H]noradrenaline release and increased [Ca2+] in SH-SY5Y human neuroblastoma cells. Br J Anaesth. 1997;79:78–83
  18. Smart D, Smith G, Lambert DG. Halothane and isoflurane enhance basal and carbachol-stimulated inositol(1,4,5)triphosphate formation in SH-SY5Y human neuroblastoma cells. Biochem Pharmacol. 1994;47:939–945
  19. Mitsuhata H, Shimizu R, Yokoyama MM. Suppressive effects of volatile anaesthetics on cytokine release in human peripheral blood mononuclear cells. Int J Immunopharmacol. 1995;17:529–534
  20. Xie Z, Dong Y, Maeda U, Moir RD, Xia W, Culley DJ, et al. The inhalation anesthetic isoflurane induces a vicious cycle of apoptosis and amyloid beta-protein accumulation. J Neurosci. 2007;27:1247–1254
  21. Xie Z, Dong Y, Maeda U, Alfille P, Culley DJ, Crosby G, et al. The common inhalation anesthetic isoflurane induces apoptosis and increases amyloid beta protein levels. Anesthesiology. 2006;104:988–994
  22. Wei H, Kang B, Wei W, Liang G, Meng QC, Li Y, et al. Isoflurane and sevoflurane affect cell survival and BCL-2/BAX ratio differently. Brain Res. 2005;1037:139–147
  23. Kuroda M, Yoshikawa D, Nishikawa K, Saito S, Goto F. Volatile anesthetics inhibit calcitonin gene-related peptide receptor-mediated responses in pithed rats and human neuroblastoma cells. J Pharmacol Exp Ther. 2004;311:1016–1022
  24. Huang Y, Zuo Z. Isoflurane enhances the expression and activity of glutamate transporter type 3 in C6 glioma cells. Anesthesiology. 2003;99:1346–1353
  25. De Rossi LW, Brueckmann M, Rex S, Barderschneider M, Buhre W, Rossaint R. Xenon and isoflurane differentially modulate lipopolysaccharide-induced activation of the nuclear transcription factor KB and production of tumor necrosis factor-α and interleukin-6 in monocytes. Anesth Analg. 2004;98:1007–1012
  26. Ke JJ, Zhan J, Feng XB, Wu Y, Rao Y, Wang YL. A comparison of the effect of total intravenous anaesthesia with propofol and remifentanil and inhalational anaesthesia with isoflurane on the release of pro- and anti-inflammatory cytokines in patients undergoing open cholecystectomy. Anaesth Intensive Care. 2008;36:74–78
  27. Wada H, Seki S, Takahashi T, Kawarabayashi N, Higuchi H, Habu Y, et al. Combined spinal and general anaesthesia attenuates liver metastasis by preserving TH1/TH2 cytokine balance. Anesthesiology. 2007;106:499–506
  28. Bedforth NM, Girling KJ, Skinner HJ, Mahajan RP. Effects of desflurane on cerebral autoregulation. Br J Anaesth. 2001;87:193–197
  29. Boisson-Bertrand D, Laxenaire MC, Mertes PM. Recovery after prolonged anaesthesia for acoustic neuroma surgery: desflurane versus isoflurane. Anaesth Intensive Care. 2006;34:338–342
  30. Kushida A, Inada T, Shingu K. Enhancement of antitumor immunity after propofol treatment in mice. Immunopharmacol Immunotoxicol. 2007;29:477–486
  31. Siddiqui RA, Zerouga M, Wu M, Castillo A, Harvey K, Zaloga GP, et al. Anticancer properties of propofol-docosahexaenoate and propofol-eicosapentaenoate on breast cancer cells. Breast Cancer Res. 2005;7:645–654
  32. Garib V, Lang K, Niggemann B, Zänker KS, Brandt L, Dittmar T. Propofol-induced calcium signalling and actin reorganization within breast carcinoma cells. Eur J Anaesthesiol. 2005;22:609–615
  33. Garib V, Niggemann B, Zänker KS, Brandt L, Kubens BS. Influence of non-volatile anesthetics on the migration behavior of the human breast cancer cell line MDA-MB-468. Acta Anaesthesiol Scand. 2002;46:836–844
  34. Saito Shibakawa Y, Sasaki Y, Goshima Y, Echigo N, Kamiya Y, Kurahashi K, et al. Effects of ketamine and propofol on inflammatory responses of primary glial cell cultures stimulated with lipopolysaccharide. Br J Anaesth. 2005;95:803–810
  35. Sikand KS, Hirota K, Smith G, Lambert DG. Etomidate inhibits [3H]noradrenaline release from SH-SY5Y human neuroblastoma cells. Neurosci Lett. 1997;236:87–90
  36. Absalom A, Pledger D, Kong A. Adrenocortical function in critically ill patients 24h after a single dose of etomidate. Anaesthesia. 1999;54:861–867
  37. Wagner RL, White PF, Kan PB, Rosenthal MH, Feldman D. Inhibition of adrenal steroidogenesis by the anesthetic etomidate. N Engl J Med. 1984;310:1415–1421
  38. Bentley MW, Stas JM, Johnson JM, Viet BC, Garrett N. Effects of preincisional ketamine treatment on natural killer cell activity and postoperative pain management after oral maxillofacial surgery. AANA J. 2005;73:427–436
  39. Chang Y, Chen TL, Sheu JR, Chen RM. Suppressive effects of ketamine on macrophage functions. Toxicol Appl Pharmacol. 2005;204:27–35
  40. Takenaka I, Ogata M, Koga K, Matsumoto T, Shigematsu A. Ketamine suppresses endotoxin-induced tumor necrosis factor alpha production in mice. Anesthesiology. 1994;80:402–408
  41. Kawasaki T, Ogata M, Kawasaki C, Ogata J, Inoue Y, Shigematsu A. Ketamine suppresses proinflammatory cytokine production in human whole blood in vitro. Anesth Analg. 1999;89:665–669
  42. Wang E, Guo QL, Hu S, Wang YJ. Effects of intravenous anesthetics on LPS-induced production of tumour necrosis factor-alpha from primary cultures of rat glial cells in vitro. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2007;32:413–416
  43. Danielian AA, Mirakian MM, Aĭrapetian SN. The dehydration action of ketamine on tumorous and normal glandular breast tissues in vitro. Eksp Klin Farmakol. 1999;62:51–54
  44. Danielian AA, Mirakian MM, Aĭrapetian SN. The dehydrating action of ketamine on malignant breast tumors. Vopr Onkol. 1998;44:395–397
  45. Lee KH, Ko BH, Paik JY, Jung KH, Choe YS, Choi Y, et al. Effects of anesthetic agents and fasting duration on 18F-FDG biodistribution and insulin levels in tumor-bearing mice. J Nucl Med. 2005;46:1531–1536
  46. Choi SJ, Kim MH, Lim SW, Gwak MS. Effect of ketamine on apoptosis by energy deprivation in astroglioma cells using flow cytometry system. J Korean Med Sci. 2005;20:113–120
  47. Lundy J, Lovett EJ, Conran P. Pulmonary metastases, a potential biologic consequence of anesthetic-induced immunosuppression by thiopental. Surgery. 1977;82:254–256
  48. Lovett EJ, Varani J, Lundy J. Suppressor cells and increased primary tumor growth rate induced by thiopental. J Surg Oncol. 1983;22:26–32
  49. Lovett EJ, Alderman J, Munster E, Lundy J. Suppressive effects of thiopental and halothane on specific arms of the immune response. J Surg Oncol. 1980;15:327–334
  50. Duncan PG, Cullen BF, Ray-Keil L. Thiopental inhibition of tumor immunity. Anesthesiology. 1977;46:97–101
  51. Ben-Eliyahu S, Shakhar G, Rosenne E, Levinson Y, Beilin B. Hypothermia in barbiturate-anesthetized rats suppresses natural killer cell activity and compromises resistance to tumor metastasis: a role for adrenergic mechanisms. Anesthesiology. 1999;91:732–740
  52. chiyama T, Nishikawa M, Lipton JM, Matsubara T, Takashi H, Furukawa S. Thiopental inhibits NF-kappaB activation in human glioma cells and experimental brain inflammation. Brain Res. 2001;911:56–61
  53. Loop T, Humar M, Pischke S, Hoetzel A, SchmidtR Pahl HL, et al. Thiopental inhibits tumor necrosis factor α-induced activation of nuclear factor kB through suppression of IkB kinase activity. Anesthesiology. 2003;99:360–367
  54. Lambert DG, Willets JM, Atcheson R, Frost C, Smart D, Rowbotham DJ, et al. Effects of propofol and thiopentone on potassium- and carbachol-evoked [3H]noradrenaline release and increased [Ca2+]i from SH-SY5Y human neuroblastoma cells. Biochem Pharmacol. 1996;51:1613–1621
  55. Coate WB, Ulland BM, Lewis TR. Chronic exposure to low concentrations of halothane-nitrous oxide: lack of carcinogenic effect in the rat. Anesthesiology. 1979;50:306–309
  56. Kano Y, Sakamoto S, Sakuraya K, Kubota T, Hida K, Suda K, et al. Effect of nitrous oxide on human bone marrow cells and its synergistic effect with methionine and methotrexate on functional folate deficiency. Cancer Res. 1981;41:4698–4701
  57. Kroes AC, Ermens AA, Lindemans J, Abels J. Effects of 5-fluorouracil treatment of rat leukemia with concomitant inactivation of cobalamin. Anticancer Res. 1986;6:737–742
  58. Kroes AC, Lindemans J, Abels J. Synergistic growth inhibiting effect of nitrous oxide and cycloleucine in experimental rat leukaemia. Br J Cancer. 1984;50:793–800
  59. Kroes AC, Lindemans J, Hagenbeek A, Abels J. Nitrous oxide reduces growth of experimental rat leukemia. Leuk Res. 1984;8:441–448
  60. Griffith CD, Kamath MB. Effect of halothane and nitrous oxide anaesthesia on natural killer lymphocytes from patients with benign and malignant breast disease. Br J Anaesth. 1986;58:540–543
  61. Ermens AA, Schoester M, Spijkers LJ, Lindemans J, Abels J. Toxicity of methotrexate in rats preexposed to nitrous oxide. Cancer Res. 1989;49:6337–6341
  62. Abels J, Kroes AC, Ermens AA, van Kapel J, Schoester M, Spijkers LJ, et al. Anti-leukemic potential of methyl-cobalamin inactivation by nitrous oxide. Am J Hematol. 1990;34(2):128–131
  63. Ermens AA, Vink N, Schoester M, van Lom K, Lindemans J, Abels J. Nitrous oxide selectively reduces the proliferation of the malignant cells in experimental rat leukaemia. Cancer Lett. 1989;45:123–128
  64. Crespo ML, Giménez A, Bas T, García C, Puertes IR, Viña JR. Effect of nitrous oxide and propofol on amino acid metabolism in neoplasic patients. Nutr Cancer. 1997;27:80–83
  65. Hopkins MP, von Gruenigen V, Haller NA, Holda S. The effect of various insufflation gases on tumor implantation in an animal model. Am J Obstet Gynecol. 2002;187:994–996
  66. Neuhaus SJ, Ellis T, Rofe AM, Pike GK, Jamieson GG, Watson DI. Tumor implantation following laparoscopy using different insufflation gases. Surg Endosc. 1998;12:1300–1302
  67. Neuhaus SJ, Watson DI, Ellis T, Rowland R, Rofe AM, Pike GK, et al. Wound metastasis after laparoscopy with different insufflation gases. Surgery. 1998;123:579–583
  68. Resendes MC, Kalogeros GC, Dixon SJ, Philp RB. Nitrous oxide enhances Na+/Ca++ exchange in the neuroblastoma cell line SK-N-SH. J Pharmacol Exp Ther. 1997;280:795–801
  69. Weber NC, Kandler J, Schlack W, Grueber Y, Frädorf J, Preckel B. Intermitted pharmacologic pretreatment by xenon, isoflurane, nitrous oxide, and the opioid morphine prevents tumor necrosis factor alpha-induced adhesion molecule expression in human umbilical vein endothelial cells. Anesthesiology. 2008;108:199–207
  70. Page GG, Blakely WP, Ben-Eliyahu S. Evidence that postoperative pain is a mediator of the tumor-promoting effects of surgery in rats. Pain. 2001;90:191–199
  71. Sacerdote P. Opioids and the immune system. Palliat Med. 2006;20:9–15
  72. El Mouedden M, Meert TF. The impact of the opioids fentanyl and morphine on nociception and bone destruction in a murine model of bone cancer pain. Pharmacol Biochem Behav. 2007;87:30–40
  73. El Mouedden M, Meert TF. Pharmacological evaluation of opioid and non-opioid analgesics in a murine bone cancer model of pain. Pharmacol Biochem Behav. 2007;86:458–467
  74. Shavit Y, Ben-Eliyahu S, Zeidel A, Beilin B. Effects of fentanyl on natural killer cell activity and on resistance to tumor metastasis in rats. Dose and timing study. Neuroimmunomodulation. 2004;11:255–260
  75. Li W, Tang HZ, Jiang YB, Xu MX. Influence of different doses of fentanyl on T-lymphocyte subpopulations and natural killer cells of patients with esophageal tumor during preoperation and postoperation. Ai Zheng. 2003;22:634–636
  76. Beilin B, Shavit Y, Hart J, Mordashov B, Cohn S, Notti I, et al. Effects of anesthesia based on large versus small doses of fentanyl on natural killer cell cytotoxicity in the perioperative period. Anesth Analg. 1996;82:492–497
  77. Beilin B, Shavit Y, Cohn S, Kedar E. Narcotic-induced suppression of natural killer cell activity in ventilated and nonventilated rats. Clin Immunol Immunopathol. 1992;64:173–176
  78. Franchi S, Panerai AE, Sacerdote P. Buprenorphine ameliorates the effect of surgery on hypothalamus–pituitary–adrenal axis, natural killer cell activity and metastatic colonization in rats in comparison with morphine or fentanyl treatment. Brain Behav Immun. 2007;21:767–774
  79. Atcheson R, Rowbotham DJ, Lambert DG. Fentanyl inhibits the release of [3H]noradrenaline from SH-SY5Y human neuroblastoma cells. Br J Anaesth. 1994;72:98–103
  80. Coles JP, Leary TS, Monteiro JN, Brazier P, Summors A, Doyle P, et al. Propofol anesthesia for craniotomy: a doubleblind comparison of remifentanil, alfentanil, and fentanyl. J Neurosurg Anesthesiol. 2000;12:15–20
  81. Tipps LB, Coplin WM, Murry KR, Rhoney DH. Safety and feasibility of continuous infusion of remifentanil in the neurosurgical intensive care unit. Neurosurgery. 2000;46:596–601
  82. Lobo F, Beiras A. Propofol and remifentanil effect-site concentrations estimated by pharmacokinetic simulation and bispectral index monitoring during craniotomy with intraoperative awakening for brain tumor resection. J Neurosurg Anesthesiol. 2007;19:183–189
  83. Djian MC, Blanchet B, Pesce F, Sermet A, Disdet M, Vazquez V, et al. Comparison of the time to extubation after use of remifentanil or sufentanil in combination with propofol as anesthesia in adults undergoing nonemergency intracranial surgery: a prospective, randomized, double-blind trial. Clin Ther. 2006;28:560–568
  84. Fodale V, Schifilliti D, Conti A, Lucanto T, Pino G, Santamaria LB. Transcranial Doppler and anesthetics. Acta Anaesthesiol Scand. 2008;52:319–326
  85. Valién JL, Hernando AN, Gascón AH, Francés RC, Lobera JC. Cellular immune response to 3 anesthetic techniques for simple abdominal hysterectomy. Rev Esp Anestesiol Reanim. 2007;54:523–528
  86. Jaeger K, Scheinichen D, Heine J, André M, Bund M, Piepenbrock S, et al. Remifentanil, fentanyl, and alfentanil have no influence on the respiratory burst of human neutrophils in vitro. Acta Anaesthesiol Scand. 1998;42:1110–1113
  87. De Leon-Casasola OA, Lema MJ. Epidural bupivacaine/sufentanil therapy for postoperative pain control in patients tolerant to opioid and unresponsive to epidural bupivacaine/morphine. Anesthesiology. 1994;80:303–309
  88. Soltész S, Biedler A, Silomon M, Schöpflin I, Molter GP. Recovery after remifentanil and sufentanil for analgesia and sedation of mechanically ventilated patients after trauma or major surgery. Br J Anaesth. 2001;86:763–768
  89. Weinstabl C, Mayer N, Richling B, Czech T, Spiss CK. Effect of sufentanil on intracranial pressure in neurosurgical patients. Anaesthesia. 1991;46:837–840
  90. Manfredi PL, Chandler SW, Patt R, Payne R. High-dose epidural infusion of opioids for cancer pain: cost issues. J Pain Symptom Manage. 1997;13:118–121
  91. El Azab SR, Rosseel PM, De Lange JJ, van Wijk EM, van Strik R, Scheffer GJ. Effect of VIMA with sevoflurane versus TIVA with propofol or midazolam-sufentanil on the cytokine response during CABG surgery. Eur J Anaesthesiol. 2002;19:276–282
  92. Helmy SA, Wahby MA, El-Nawaway M. The effect of anaesthesia and surgery on plasma cytokine production. Anaesthesia. 1999;54:733–738
  93. Wiffen PJ, McQuay HJ. Oral morphine for cancer pain. Cochrane Database Syst Rev. 2007;4:CD003868
  94. Miura H, Taira O, Hiraguri S, Kato H. Morphine for the management of pain in lung cancer. Nippon Rinsho. 2002;60:676–680
  95. Donnelly S, Davis MP, Walsh D, Naughton M, World Health Organization . Morphine in cancer pain management: a practical guide. Support Care Cancer. 2002;10:13–35
  96. Kato Y, Kato A. Role of continuous intravenous infusion of morphine in the cancer pain relieving therapy. Nippon Rinsho. 2001;59:1789–1793
  97. Gilmer-Hill HS, Boggan JE, Smith KA, Wagner FC. Intrathecal morphine delivered via subcutaneous pump for intractable cancer pain: a review of the literature. Surg Neurol. 1999;51:12–15
  98. Simon RH, Arbo TE. Morphine increases metastatic tumor growth. Brain Res Bull. 1986;16:363–367
  99. Yeager MP, Colacchio TA. Effect of morphine on growth of metastatic colon cancer in vivo. Arch Surg. 1991;126:454–456
  100. Kuraishi Y. Effects of morphine on cancer pain and tumor growth and metastasis. Nippon Rinsho. 2001;59:1669–1674
  101. Sasamura T, Nakamura S, Iida Y, Fujii H, Murata J, Saiki I, et al. Morphine analgesia suppresses tumor growth and metastasis in a mouse model of cancer pain produced by orthotopic tumor inoculation. Eur J Pharmacol. 2002;441:185–191
  102. Sacerdote P, Bianchi M, Gaspani L, Manfredi B, Maucione A, Terno G, et al. The effects of tramadol and morphine on immune responses and pain after surgery in cancer patients. Anesth Analg. 2000;90:1411–1414
  103. Harimaya Y, Koizumi K, Andoh T, Nojima H, Kuraishi Y, Saiki I. Potential ability of morphine to inhibit the adhesion, invasion and metastasis of metastatic colon 26-L5 carcinoma cells. Cancer Lett. 2002;187:121–127
  104. Tegeder I, Grösch S, Schmidtko A, Häussler A, Schmidt H, Niederberger E, et al. G protein-independent G1 cell cycle block and apoptosis with morphine in adenocarcinoma cells: involvement of p53 phosphorylation. Cancer Res. 2003;63:1846–1852
  105. Hatsukari I, Hitosugi N, Ohno R, Hashimoto K, Nakamura S, Satoh K, et al. Induction of apoptosis by morphine in human tumor cell lines in vitro. Anticancer Res. 2007;27:857–864
  106. Hatsukari I, Hitosugi N, Matsumoto I, Nagasaka H, Sakagami H. Induction of early apoptosis marker by morphine in human lung and breast carcinoma cell lines. Anticancer Res. 2003;23:2413–2417
  107. Cheng WF, Chen LK, Chen CA, Chang MC, Hsiao PN, Su YN, et al. Chimeric DNA vaccine reverses morphine-induced immunosuppression and tumorigenesis. Mol Ther. 2006;13:203–210
  108. King T, Vardanyan A, Majuta L, Melemedjian O, Nagle R, Cress AE, et al. Morphine treatment accelerates sarcoma-induced bone pain, bone loss, and spontaneous fracture in a murine model of bone cancer. Pain. 2007;132:154–168
  109. Hashiguchi S, Morisaki H, Kotake Y, Takeda J. Effects of morphine and its metabolites on immune function in advanced cancer patients. J Clin Anesth. 2005;17:575–580
  110. Chrubasik S, Chrubasik J, Friedrich G. Clinical use of alfentanil. Anaesthesiol Reanim. 1994;19:60–66
  111. Cairns R. The use of oxycodone in cancer-related pain: a literature review. Int J Palliat Nurs. 2001;7:522–527
  112. Biancofiore G. Oxycodone controlled release in cancer pain management. Ther Clin Risk Manage. 2006;2:229–234
  113. Kumar MG, Lin S. Hydromorphone in the management of cancer-related pain: an update on routes of administration and dosage forms. J Pharm Pharm Sci. 2007;10:504–518
  114. Sacerdote P, Bianchi M, Manfredi B, Panerai AE. Effects of tramadol on immune responses and nociceptive thresholds in mice. Pain. 1997;72:325–330
  115. Gaspani L, Bianchi M, Limiroli E, Panerai AE, Sacerdote P. The analgesic drug tramadol prevents the effect of surgery on natural killer cell activity and metastatic colonization in rats. J Neuroimmunol. 2002;129:18–24
  116. Amann A, Rieder J, Fleischer M, Niedermüller P, Hoffmann G, Amberger A, et al. The influence of atracurium, cisatracurium, and mivacurium on the proliferation of two human cell lines in vitro. Anesth Analg. 2001;93:690–696
  117. Magorian T, Wood P, Caldwell J, Fisher D, Segredo V, Szenohradszky J, et al. The pharmacokinetics and neuromuscular effects of rocuronium bromide in patients with liver disease. Anesth Analg. 1995;80:754–759
  118. Sessler DI. Does regional analgesia reduce the risk of cancer recurrence? A hypothesis. Eur J Cancer Prev. 2008;17:269–272
  119. Sessler DI. Regional anaesthesia and cancer recurrence risk. Rev Esp Anestesiol Reanim. 2008;55:133–134
  120. Arain MR, Buggy DJ. Anaesthesia for cancer patients. Curr Opin Anaesthesiol. 2007;20:247–253
  121. Groetelaers RP, van Berlo CL, Nijhuis PH, Schapers RF, Gerritsen HA. Axillary recurrences after negative sentinel lymph node biopsy under local anaesthesia for breast cancer: a follow-up study after 5 years. Eur J Surg Oncol. 2008;[Epub ahead of print]
  122. Kumar CM, Corbett WA, Wilson RG. Spinal anaesthesia with a micro-catheter in high-risk patients undergoing colorectal cancer and other major abdominal surgery. Surg Oncol. 2008;17:73–79
  123. Greengrass R, O'Brien F, Lyerly K, Hardman D, Gleason D, D'Ercole F, et al. Paravertebral block for breast cancer surgery. Can J Anaesth. 1996;43:858–861
  124. Hashimoto T, Hashimoto S, Hori Y, Nakagawa H, Hosokawa T. Epidural anaesthesia blocks changes in peripheral lymphocytes subpopulation during gastrectomy for stomach cancer. Acta Anaesthesiol Scand. 1995;39:294–298
  125. Sharma S, Rajagopal MR, Palat G, Singh C, Haji AG, Jain D. A phase II pilot study to evaluate use of intravenous lidocaine for opioid-refractory pain in cancer patients. J Pain Symptom Manage. 2008;[Epub ahead of print]
  126. Massey GV, Pedigo S, Dunn NL, Grossman NJ, Russell EC. Continuous lidocaine infusion for the relief of refractory malignant pain in a terminally ill pediatric cancer patient. J Pediatr Hematol Oncol. 2002;24(7):566–568
  127. Sakaguchi M, Kuroda Y, Hirose M. The antiproliferative effect of lidocaine on human tongue cancer cells with inhibition of the activity of epidermal growth factor receptor. Anesth Analg. 2006;102:1103–1107
  128. Mammoto T, Higashiyama S, Mukai M, Mammoto A, Ayaki M, Mashimo T, et al. Infiltration anesthetic lidocaine inhibits cancer cell invasion by modulating ectodomain shedding of heparin-binding epidermal growth factor-like growth factor (HB-EGF). J Cell Physiol. 2002;192:351–358
  129. Martinsson T, Fowler CJ. Local anaesthetics do not affect protein kinase C function in intact neuroblastoma cells. Life Sci. 1993;53:1557–1565
  130. Di Padova M, Barbieri R, Fanciulli M, Arcuri E, Floridi A. Effect of local anesthetic ropivacaine on the energy metabolism of Ehrlich ascites tumor cells. Oncol Res. 1998;10:491–498
  131. Feinstein DL, Murphy P, Sharp A, Galea E, Gavrilyuk V, Weinberg G. Local anesthetics potentiate nitric oxide synthase type 2 expression in rat glial cells. J Neurosurg Anesthesiol. 2001;13:99–105
  132. Villar-Garea A, Fraga MF, Espada J, Esteller M. Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. Cancer Res. 2003;63:4984–4989
  133. Mariggiò MA, Cafaggi S, Ottone M, Parodi B, Vannozzi MO, Mandys V, et al. Inhibition of cell growth, induction of apoptosis and mechanism of action of the novel platinum compound cis-diaminechloro-[2-(diethylamino) ethyl 4-amino-benzoate, N(4)]-chloride platinum (II) monohydrochloride monohydrate. Invest New Drugs. 2004;22:3–16
  134. Viale M, Pastrone I, Pellecchia C, Vannozzi MO, Cafaggi S, Esposito M. Combination of cisplatin–procaine complex DPR with anticancer drugs increases cytotoxicity against ovarian cancer cell lines. Anticancer Drugs. 1998;9(5):457–463
  135. Angileri FF, Aguennouz M, Conti A, La Torre D, Cardali S, Crupi R, et al. Nuclear factor-kappaB activation and differential expression of survivin and Bcl-2 in human grade 2-4 astrocytomas. Cancer. 2008;112(10):2258–2266
  136. Sessler DI, Ben-Eliyahu S, Mascha EJ, Parat MO, Buggy DJ. Can regional analgesia reduce the risk of recurrence after breast cancer? Methodology of a multicenter randomized trial. Contemp Clin Trials. 2008;29:517–526

PII: S0960-7404(09)00043-7

doi: 10.1016/j.suronc.2009.03.007

Surgical Oncology
Volume 19, Issue 2 , Pages 63-81 , June 2010

Article Tools